- Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
American heart journal (2014-06-24)
Rury R Holman, Mary A Bethel, Juliana C N Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan
PMID24952856
ABSTRACT
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
MATERIALS
Product Number
Brand
Product Description
Acarbose for peak identification, European Pharmacopoeia (EP) Reference Standard
Acarbose for identification, European Pharmacopoeia (EP) Reference Standard
Acarbose, European Pharmacopoeia (EP) Reference Standard